FILE PHOTO: Gilead Sciences Inc pharmaceutical company is seen after they announced a Phase 3 Trial of the investigational antiviral drug Remdesivir in patients with severe coronavirus disease , during the outbreak of the coronavirus disease , in Oceanside, California, U.S., April 29, 2020. REUTERS/Mike Blake/File Photo
- India’s drug regulator has given Hetero Labs the green light to manufacture and market its generic version of Gilead Science’s experimental COVID-19 treatment remdesivir, the Indian pharmaceutical company said on Sunday. The drug, which will be marketed under the brand name Covifor, will likely be priced at 5,000 to 6,000 rupees for a 100 milligram dose, Hetero said.
India's Cipla Ltd has also received approval from the Drug Controller General of India to manufacture and market the drug, according to a reportGilead Sciences Inc signed non-exclusive licensing pacts last month with five generic drugmakers based in India and Pakistan to expand the supply of its COVID-19 treatment.
The pacts allow Jubilant Life Sciences Ltd, Cipla, Hetero Labs, Mylan NV and Ferozsons Laboratories Ltd to make and sell the drug in 127 countries.
Is the stonk market down or something?
This is very homophobic jccisneros92
How homophobic of them
To all the LGBTQ folks who are getting upset about the name of the pharma company, a few years back there was similar furor about Hitler Jeans. Indian choices for names do not always adhere to Western sensibilities, but malice is rarely intended.
Hetero labs? As a gay man, I'm concerned.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: Reuters - 🏆 2. / 97 Read more »